The European Group for Blood and Marrow Transplantation regularly publishes 
special reports on the current practice of haematopoietic SCT for haematological 
diseases, solid tumours and immune disorders in Europe. Major changes have 
occurred since the first report was published. HSCT today includes grafting with 
allogeneic and autologous stem cells derived from BM, peripheral blood and cord 
blood. With reduced-intensity conditioning regimens in allogeneic 
transplantation, the age limit has increased, permitting the inclusion of older 
patients. New indications have emerged, such as autoimmune disorders and AL 
amyloidosis for autologous HSCT and solid tumours, myeloproliferative syndromes 
and specific subgroups of lymphomas for allogeneic transplants. The introduction 
of alternative therapies, such as imatinib for CML, has challenged 
well-established indications. An updated report with revised tables and 
operating definitions is presented.